Company intelligence / Profile preview
Xspray Pharma
Stockholm, Swedenxspraypharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Xspray Pharma develops improved amorphous versions of marketed protein kinase inhibitors (PKIs) for cancer treatment. Their lead product Dasynoc (dasatinib) is awaiting final FDA approval with anticipated launch on September 1, 2024. Their second product candidate XS003 (nilotinib) has demonstrated matching bioavailability with Tasigna at a reduced dose and is expected to be submitted to FDA in first half of 2025.[1][5][7]
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesamorphous solid dispersion (ASD) formulations
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on Xspray Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xspray Pharma.